KEGG   DRUG: Belantamab mafodotin
Entry
D11595                      Drug                                   

Name
Belantamab mafodotin (USAN);
Belantamab mafodotin (genetical recombination) (JAN);
Belantamab mafodotin-blmf;
Blenrep (TN)
Product
Formula
C6484H10008N1728O2030S44. (C49H66N6O11)4
Exact mass
149625.9884
Mol weight
149718.3897
Remark
ATC code: L01XC39
Product: D11595<US>
Efficacy
Antineoplastic
  Disease
Multiple myeloma [DS:H00010]
Comment
Antibody-drug conjugate
Treatment of multiple myeloma
Target
TNFRSF17 (BCMA, CD269) [HSA:608] [KO:K05153]
TUBB [HSA:10381 10382 10383 203068 347688 347733 7280 81027 84617] [KO:K07375]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04672  Intestinal immune network for IgA production
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01X OTHER ANTINEOPLASTIC AGENTS
    L01XC Monoclonal antibodies
     L01XC39 Belantamab mafodotin
      D11595  Belantamab mafodotin (USAN) <US>
USP drug classification [BR:br08302]
 Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Belantamab Mafodotin
    D11595  Belantamab mafodotin (USAN)
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokine receptors
   Tumor necrosis factor receptors
    TNFRSF17 (BCMA, CD269)
     D11595  Belantamab mafodotin (USAN) <US>
 Not elsewhere classified
  Cellular process
   Cytoskeleton
    TUBB
     D11595  Belantamab mafodotin (USAN) <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11595
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D11595
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11595
Other DBs
PubChem: 405226462
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system